<b>Conclusions:</b> These findings suggest that FOXM1, MCM3, SH3BP5, and PAPSS2 could serve as biomarkers for early prognosis, diagnosis, and targeted therapy in patients with cervical and ovarian cancer. This evidence concerns the gene MCM3 and ovarian cancer.